Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients

Al-Maarif University College150 enrolled

Overview

This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).

The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP+HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Head and Neck Cancer Chronic Periodontitis Radiotherapy Side Effect

Interventions

RadiationRADIATION

HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months

Eligibility

Sex: ALLMin age: 28 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * A pathologically confirmed malignant neoplasm of HNC (derived from epithelial cells). * Not having received radiation therapy previously. * No distant metastasis. * No history of salivary gland surgery (parotid, submandibular, or sublingual). * A generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability. Exclusion Criteria: * Previous oral disease or salivary gland disease history. * Definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease. * Refusal to participate in the study.

Locations (1)

Ahmed A. Al-Kubaisi

Ramadi, Al-Anbar Governorate, Iraq

Outcomes

Primary Outcomes

Measure of serum suPAR level

Measure of serum suPAR level in patients head and neck cancer who received radiotherapy

Time frame: 6 months

Clinical Periodontal parameters measured

Periodontal parameters included (CAL, PI, GBI, PPD) measured by using a millimeter periodontal probe in patients with head and neck cancer who received radiotherapy.

Time frame: 6 months

Secondary Outcomes

Oral pH-saliva was measured

Oral pH-saliva collected from outcomes and measured pH-saliva by using pH-meter in patients who underwent radiotherapy.

Time frame: 6 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.